

DEC 02 2002  
PATENT & TRADEMARK OFFICE

Patent  
Attorney Docket No. 541138004.US01

16328

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on:

Date: November 25, 2002

By: Miyabi Grace

*Miyabi Grace*

#12

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: ALISON, Malcolm R. *et al.*

APPLICATION No.: 09/769,204

FILED: January 24, 2001

FOR: COMBINATION AND METHODS FOR PROMOTING *IN VIVO* LIVER CELL PROLIFERATION AND ENHANCING *IN VIVO* LIVER-DIRECTED GENE TRANSDUCTION

EXAMINER: DAN SULLIVAN

ART UNIT: 1632

**RECEIVED**

DEC 05 2002

TECH CENTER 1600/2900

**FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement (“IDS”) are brought to the attention of the Office. The items are listed on the attached Form PTO-1449 as items AL-BG. Pursuant to 37 C.F.R. 1.98(d)(1), Applicant respectfully requests the Examiner to refer to U.S. Patent No. 6,248,725, formerly U.S. Patent Application No. 09/256,630, which this current application relies on for an earlier effective filing date under 35 U.S.C. 120, for copies of the references.

The items identified in this IDS may or may not be “material” pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as “prior art” under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

**INFORMATION DISCLOSURE STATEMENT FILING PROVISION:**

This IDS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action on the merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311.

The fee due under 37 CFR § 1.17(p) is submitted herewith.

**PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:**

A check in the amount of \$180.00 is enclosed for the above fee(s).

The Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to Deposit Account No. **50-0665**.

Respectfully submitted,  
Perkins Coie LLP

Dated: 11/25/02

By: Lauren Sliger  
Lauren Sliger  
Registration No. 51,086

Perkins Coie LLP  
Patent – LA  
P.O. Box 1208  
Seattle, WA 98111-1208  
Phone: (310) 788-9900  
Fax: (310) 788-3399



34055  
PATENT TRADEMARK OFFICE